Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moleculin Biotech, Inc. - Common Stock (NQ: MBRX )

2.180 +0.910 (+71.65%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Moleculin Biotech, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Friday's session: top gainers and losers
Here are the top movers in Friday's session, showcasing the stocks with significant price changes. 
Via Chartmill
Check out the stocks that are attracting the most attention and driving market activity.
Let's dive into the action on the US markets on Friday. Here are the most active stocks that are driving the market today. 
Via Chartmill
Unusual volume stocks in Friday's session
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume. 
Via Chartmill
What's going on in today's session
Here are the top movers in Friday's session, showcasing the stocks with significant price changes. 
Via Chartmill
Insights Ahead: Moleculin Biotech's Quarterly Earnings
Via Benzinga
MBRX Stock Earnings: Moleculin Biotech Reported Results for Q4 2023
Moleculin Biotech just reported results for the fourth quarter of 2023. 
Via InvestorPlace
A Preview Of Moleculin Biotech's Earnings
Via Benzinga
Top movers in Friday's pre-market session
Before the US market kicks off on Friday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
US Stocks Set For A Volatile Start: Analyst Dismisses Chances Of 20%+ S&P 500 Gain For Third Year In A Row, But Says 'Investors Should Be Optimistic'
U.S. stock futures traded close to the flatline on Friday after Tuesday's rally. Futures of all four benchmark indices were slightly lower. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Airbnb Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Keep an eye on the top gainers and losers in Thursday's session.
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements. 
Via Chartmill
The trading volume of these stocks is deviating from the norm in today's session.
The trading volume of these stocks is deviating from the norm in today's session. 
Via Chartmill
Which stocks are moving on Thursday?
Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday?
Moleculin Biotech received FDA guidance reducing its Phase 3 trial size for Annamycin in AML. First unblinding is expected in late 2025, with another in 2026. 
Via Benzinga
Exposures Product Safety
Thursday's session: gap up and gap down stocks
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Thursday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
Unusual volume stocks in Wednesday's session
On Wednesday, there are stocks with unusual volume. Let's take a look. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Coherent Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
What's Going On With Moleculin Biotech Shares Wednesday?
Moleculin Biotech shares are trading higher on Wednesday after the company announced the online publication of preclinical data for its Annamycin Venetoclax Resistant AML model. 
Via Benzinga
MBRX Stock Earnings: Moleculin Biotech Beats EPS for Q2 2024
MBRX stock results show that Moleculin Biotech beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
MBRX Stock Earnings: Moleculin Biotech Beats EPS for Q1 2024
MBRX stock results show that Moleculin Biotech beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Earnings Scheduled For March 22, 2024
Companies Reporting Before The Bell • Agile Therapeutics (NASDAQ:AGRX) is likely to report quarterly loss at $0.54 per share on revenue of $9.20 million. 
Via Benzinga
Micron, Signet Jewelers And 3 Stocks To Watch Heading Into Wednesday
With U.S. stock futures trading lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.